Trial Profile
An Extension Study to Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2017
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Veliparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Abbott Laboratories
- 28 Nov 2017 New trial record